Provaris Energy Ltd (ASX:PV1, OTC:GBBLF) is trading at a deep discount to risked net asset value (NAV), offering investors leveraged exposure to the energy transition and emerging carbon capture and storage (CCS) markets.
In Research as a Service (RaaS)’s latest update report on Provaris, it values the company at $0.10–0.17 per share with a midpoint net asset value (NAV) of $0.14, compared with a recent share price of $0.016.
BioHarvest Sciences Inc. (NASDAQ:BHST), a biotechnology company known for its patented Botanical Synthesis technology, reported a 39% increase in third-quarter revenue, driven by growth in its core VINIA capsule business and expanding contract development and manufacturing (CDMO) operations.
Total revenues for the quarter ended September 30 rose to $9.1 million, in line with management guidance. The company said its US active VINIA users now exceed 75,000.
Happy Creek Minerals Ltd. (TSX-V:HPY, OTC:HPYCF) has been awarded a ‘Long’ rating by Hallgarten & Company in their initial coverage of the company, with a price target of $0.32, which suggests upside of almost 150% from current levels.
The ‘Long’ rating indicates potential capital appreciation to Hallgarten’s target price during the next 12 months, reflecting the firm’s view that Happy Creek is well-positioned to benefit from both rising Tungsten prices and its development plans.
Bitfarms (TSX-V:BITF) on Thursday reported a third quarter 2025 GAAP loss of $0.08 per share, compared with a deficit of $0.05 per share a year earlier, as the company plans to transition from Bitcoin mining to becoming a North American energy and digital infrastructure company.
Analysts, on average, were expecting a loss of $0.02 per share.
Ideal Power Inc (NASDAQ:IPWR) said on Thursday it is positioning for growth in electric vehicle and data center markets after securing a development order from Stellantis for its patented B-TRAN semiconductor technology.
The company said the purchase order covers custom development and packaged B-TRAN devices for multiple EV applications, with the first of five deliverables already completed and the remainder expected next year.
Candel Therapeutics Inc (NASDAQ:CADL) reported encouraging clinical progress across its cancer immunotherapy pipeline, along with the release of its third quarter 2025 financial results.
The company recently presented new Phase 3 subgroup analyses of CAN-2409 in localized prostate cancer showing statistically significant improvement in disease-free survival and updated survival data from its Phase 1b CAN-3110 trial in recurrent high-grade glioma, underscoring the potential of its multimodal immunotherapies.
Medicus Pharma (NASDAQ:MDCX) said on Thursday it has received full regulatory and ethical approvals in the UK to expand its ongoing Phase 2 clinical trial evaluating its Doxorubicin Microneedle Array (D-MNA) treatment for basal cell carcinoma (BCC), a common form of skin cancer.
The UK’s Medicines and Healthcare products Regulatory Agency, Health Research Authority and Wales Research Ethics Committee granted the approvals, allowing Medicus to add clinical sites in the country to its ongoing study (SKNJCT-003), which is already underway across nine sites in the US.
NEXE Innovations Inc (TSX-V:NEXE, OTC:NEXNF) reported the successful delivery of more than 300,000 BPI-certified compostable coffee pods to its partner, Bridgehead Coffee, as part of the previously announced purchase order of 1.2 million pods supporting Bridgehead’s planned rollout in Costco stores across Ontario.
The compostable and innovative materials company said it is the first partial delivery of the NEXE BPI-certified compostable coffee pods under the previously announced purchase order for Bridgehead’s planned Costco launch.
Immunic Inc (NASDAQ:IMUX) highlighted positive clinical results for its lead drug candidate, vidofludimus calcium, showing statistically significant improvement in progressive multiple sclerosis (MS), as the company reported its third quarter 2025 financial results and provided a corporate update.
At the 41st Congress of ECTRIMS in September, Immunic presented data from the Phase 2 CALLIPER trial, which showed a greater than two-fold probability of 24-week confirmed disability improvement versus placebo in patients with progressive multiple sclerosis (PMS). The findings were consistent across subgroups and endpoints, supporting the drug’s neuroprotective potential and its proposed Nurr1 activation mechanism.
First Phosphate Corp. (CSE:PHOS, OTCQX:FRSPF) said it applauds the announcement by the Canadian Minister of Government Transformation, Public Works and Procurement, Joël Lightbound, to invest $57.6 million to build the second wharf at Port Saguenay in Quebec.
The mineral development and cleantech company said the second wharf is to be positioned directly adjacent to First Phosphate's planned phosphoric acid plant and will greatly assist in the transportation of the company's future phosphate concentrate, phosphoric acid and lithium iron phosphate (LFP) products to North American, European and international destinations.
NanoViricides (NYSE-A:NNVC) said on Thursday it had closed a $6 million registered direct offering with a single healthcare institutional investor to support working capital and general corporate purposes.
The Connecticut-based biotechnology company sold about 3.57 million shares of common stock, or equivalents, at $1.68 per share.
GoviEx Uranium Inc (TSX-V:GXU, OTCQB:GVXXF) reported that it has completed its previously announced plan of arrangement with Tombador Iron, making GoviEx a wholly owned subsidiary of Tombador.
Under the transaction, the combined entity will operate as a uranium exploration and development company to be re-listed by November 20 on the Australian Securities Exchange under the name Atomic Eagle, with the ticker symbol ‘AEU.’
G Mining Ventures Corp (TSX:GMIN, OTCQX:GMINF) reported third quarter 2025 gold production that rose 9% quarter over quarter to 46,360 ounces, boosted by continued strong throughput and recoveries at its Tocantinzinho Gold Mine in Brazil.
The mining company also posted record free cash flow for the quarter of US$95.8 million, an increase of 59% from Q2 2025, on a record US$161.7 million in revenue.
Imaging Biometrics Ltd (LSE:IBAI, OTCQB:IQAIF) shares rose 13% to 1.02p on Thursday after the company announced that its fractional tumour burden (FTB) mapping technology is being used in a glioblastoma (GBM) phase 2 feasibility study led by Dr Danielle Bazer at MD Anderson Cancer Center at Cooper University.
The trial is assessing whether giving temozolomide before radiotherapy can provide an early, reliable measure of drug activity in newly diagnosed high-grade glioma.
East Star Resources surged 29% to 2.58p on Thursday after striking what it described as a “transformational” joint venture with Endeavour Mining, giving the junior explorer a well-funded partner to accelerate gold exploration on two underexplored mineral belts in Kazakhstan.
Under the binding earn-in agreement, Endeavour can acquire up to 80% of a newly formed joint venture company through staged investment. It will earn 51% by spending $5 million within the first two years, rising to 70% with an additional $20 million over the next three. A final 10% would be secured by fully funding and completing a NI 43-101 pre-feasibility study.
Helium One Global Ltd (AIM:HE1, OTCQB:HLOGF) audited results for the twelve months to 30 June, released today, highlighted progress across its Tanzania and US assets, with chair James Smith calling it a "significant and successful year".
In the period, the exploration company confirmed a helium discovery at the southern Rukwa project following an extended well test at the ITW-1 well, which recorded sustained helium concentrations above 5%. The project advanced to the development stage after the formal award of a mining licence.
Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF) has reported progress in its Phase 3 drilling at Target A1, part of the Mushima North project in Zambia, where it has so far completed four reverse circulation holes for a total of 481 metres.
Field activities were, however, paused earlier than expected amid heavy rains.
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has turned to the market for fresh investment, raising £2.75 million with a share issue as it works to stabilise the business and push forward with new sexual health products.
The fundraising comes as the company continues to grapple with slower-than-expected sales of its flagship erectile dysfunction gel, Eroxon, and prepares for a pivotal year of clinical data and commercial decisions.
DroneShield Ltd (ASX:DRO, OTC:DRSHF) shares slumped 25% to a four-month low of $2.42 on Thursday after disclosures revealed that chief executive Oleg Vornik, chairman Peter James and director Jethro Marks had sold all of their ordinary shares in recent days.
The stock is now testing its 200-day moving average at $2.45 for the first time since April and has fallen about 64% from its record high earlier this year.
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) reported its financial results for the quarter ended September 30, 2025, which was dominated by regulatory and operational preparation for the PARADIGM pivotal trial of the DurAVR® transcatheter heart valve (THV), with the company subsequently announcing in November that the US Food and Drug Administration (FDA) had approved commencement of patient recruitment* in the United States.
In Europe, Denmark granted approval in October, and the first PARADIGM patients were enrolled and treated there soon after.